NCT06807424

A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-experienced Participants With Active Psoriatic Arthritis

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 750 (estimated)
• Sponsor: Janssen Research & Development, LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in biologic-experienced participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.

Conditions

• Arthritis, Psoriatic

Interventions

Type	Name	Description
DRUG	Icotrokinra	Icotrokinra will be administered.
DRUG	Placebo	Placebo will be administered.

Timeline

• Start date: 2025-01-09
• Primary completion: 2027-02-10
• Completion: 2028-10-18
• First posted: 2025-02-04
• Last updated: 2026-04-13

Locations

214 sites across 23 countries: United States, Argentina, Australia, Brazil, Bulgaria, Canada, China, Czechia, Denmark, Germany, Hong Kong, Hungary, India, Italy, Japan, Malaysia, Mexico, Poland, Romania, Spain, Taiwan, Thailand, United Kingdom

Regulatory

• FDA-regulated drug study